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High prevalence of cigarette smoking in HIV patients is associated with increased HIV
pathogenesis and disease progression. While the effect of smoking on the occurrence
of lung cancer has been studied extensively, the association between smoking and HIV
pathogenesis is poorly studied. We have recently shown the possible role of cytochrome
P450 (CYP) in smoking/nicotine-mediated viral replication. In this review, we focus on
the potential role of CYP pathway in polycyclic aromatic hydrocarbons (PAH), important
constituents of cigarette smoke, mediated HIV pathogenesis. More specifically, we will
discuss the role of CYP1A1 and CYP1B1, which are the major PAH-activating CYP
enzymes. Our results have shown that treatment with cigarette smoke condensate (CSC)
increases viral replication in HIV-infected macrophages. CSC contains PAH, which are
known to be activated by CYP1A1 and CYP1B1 into procarcinogens/toxic metabolites.
The expression of these CYPs is regulated by aryl hydrocarbon receptors (AHR), the
cellular target of PAH, and an important player in various diseases including cancer.
We propose that PAH/AHR-mediated CYP pathway is a novel target to develop new
interventions for HIV positive smokers.
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Introduction
According to the world health organization (WHO), human immunodeficiency virus (HIV) is the
world’s leading infectious killer with about 40 million reported deaths since early 1980s. Currently,
about 35 million people worldwide are estimated to be living with HIV infection or acquired
immunodeficiency syndrome (AIDS). As per the center for disease control and prevention (CDC),
although the rate of HIV incidence has stabilized in United States, about 50,000 new infections are
added to the existing HIV positive population every year.
Tobacco use, cigarette smoking in particular, is highly prevalent amongst HIV-infected pop-
ulations (Ueda et al., 1989). Several studies have reported 2–3 fold higher prevalence of cigarette
smoking in HIV positive patients as compared to general population (Crothers et al., 2009; Tesoriero
et al., 2010; Browning et al., 2013). Moreover, numerous independent factors impeding the cessation
of cigarette smoking amongst HIV population have been identified. Lower socioeconomic parame-
ters or existingmental illness, for instance, significantly correlates with the rates of cigarette smoking
and failure to quit smoking (Shirley et al., 2013). Importantly, concurrent drug use and/or history
of substance abuse have been identified as critical factors governing cigarette smoking status in HIV
infected individuals (Shirley et al., 2013; Pacek et al., 2014; O’Cleirigh et al., 2015).
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In HIV patients, chronic cigarette smoking is known to be
a major contributor toward non-AIDS related health issues.
Some of the major smoking-mediated complications reported in
HIV-infected smokers include increased incidence of pneumonia
(Feldman and Anderson, 2013b; Harboe et al., 2014), respiratory
infections (Feldman and Anderson, 2013a), low bone mineral
density (Kooij et al., 2015), cardiovascular diseases (Smith et al.,
2011; Esser et al., 2013), and non-AIDS cancer (Shiels et al., 2010;
Smith et al., 2011). In addition to these non-AIDS complications,
themost significant deleterious effect of cigarette smoking in HIV
smokers is that on HIV pathogenesis (see Impact of Smoking on
HIV Pathogenesis).
This review summarizes the findings from literature examining
the impact of cigarette smoking onHIV pathogenesis. Specifically,
the role of main constituents of cigarette, nicotine and polycyclic
aromatic hydrocarbons (PAH), in smoking-mediated increased
viral replication has been discussed. Furthermore, the contri-
bution of metabolic enzymes cytochrome P450s (CYPs) toward
the observed effects of smoking on HIV replication has been
reviewed.
Smoking and HIV
The predisposition of HIV-infected individuals toward cigarette
smoking has resulted in numerous studies examining the effects of
cigarette smoking on HIV pathogenesis and vice versa. Moreover,
multiple underlyingmechanisms governing the effects of smoking
on HIV have been reported.
Impact of HIV Infection on Smoking
Long-term effects of HIV infection are known to cause emer-
gence of the mental health issues including depression (Rueda
et al., 2014). Depression is highly prevalent amongst the aging
HIV-infected population, which requires a number of treatment
modalities including the psychopharmacologic strategies (Ben-
ton, 2008). Depression has been found to have significant correla-
tion with enhanced HIV pathogenesis (Rivera-Rivera et al., 2014)
andAIDS-related death, especially in womenwith terminal illness
(Cook et al., 2004). Importantly, several studies have reported
a close association between depression and cigarette smoking
and a heightened inability to quit cigarette smoking by depressed
patients (Anda et al., 1990; Breslau et al., 1993; Hayes et al., 2010).
For example, in a study comprising 273 subjects the odds of
quitting smoking has been found to be relatively lower in the
individuals with depressed mood compared with non-depressed
individuals. Moreover, medically ill smokers with poor quality
of life may need more intensive smoking cessation interventions
that includes mood management to help them quit smoking.
Therefore, based on the existing literature, it can be rationalized
that HIV-associated depression is perhaps a major factor that
modulates cigarette smoking habits in HIV-infected patients.
Impact of Smoking on HIV Pathogenesis
Direct impact of cigarette smoking on HIV replication and
progression to AIDS has been examined in several cohort
studies. As reviewed by Marshall et al. (2009) various studies
have demonstrated a significant relationship between cigarette
smoking and rapid decline in CD4 counts, higher risk of
developing AIDS, increased risk of acquiring other infections, and
enhanced mortality. Among the various observations reported in
HIV smokers, the effects of cigarette smoking on plasma viral load
in HIV-infected individual is a critical representation for HIV
pathogenesis. In seropositive women, for instance, current smok-
ing status significantly correlated with increased plasma viral load
(Wojna et al., 2007). Similarly, in a cohort of low-income women,
cigarette smoking was reported to have a significant impact on
chances of achieving desirable virologic responses (Feldman
et al., 2006). A study that examined the effects of smoking among
older HIV-positive gay and bisexual individuals reported similar
results, wherein cigarette smoking status correlated with lower
CD4 counts and higher viral loads (Ompad et al., 2014). Further
data analysis in this study revealed that current smokers were
significantly less likely to have undetectable plasma viral loads
compared to former- and non-smokers. A recent study also
reported higher chances of detectable plasma viral load in HIV
positive smokers compared to HIV infected non-smokers, which
further supports the existing data on cigarette-mediated enhanced
HIV pathogenesis (O’Cleirigh et al., 2015). Results from our work
corroborates smoking-mediated increased viral replication in
HIV-infected smokers compared to HIV positive non-smokers
(Ande et al., 2015). Moreover, enhanced p24 levels were observed
in HIV-infected macrophages treated with cigarette smoke
condensate (CSC) compared to vehicle treated cells thereby
providing direct evidence for the impact of cigarette constituents
on viral replication in major HIV reservoir. In addition, as
reviewed previously, negative impact of smoking on adherence
to antiretroviral therapy can be rationalized to worsen the effects
of cigarette smoking on HIV pathogenesis (Kumar et al., 2015).
Smoking-Mediated Enhanced HIV Replication:
Implicated Mechanisms
Several cellularmechanisms have been implicated in the smoking-
mediated enhanced viral replication. A study that examined the in
vitro effects of tobacco smoke extract (TSE), for instance, reported
enhanced viral replication in TSE treated cells as compared to
vehicle-treated control cells (Zhao et al., 2010). Importantly, TSE
treatment ofHuman Jurkat T-cellswas accompanied by significant
alterations in expression of several genes. Specifically, expres-
sion of genes that facilitate HIV infectivity were observed to
be upregulated, while genes regulating cellular redox function
were significantly downregulated in TSE treated cells. Overall,
these changes were rationalized to facilitate the enhanced HIV
replication associated with TSE treatment.
Increased cellular oxidative stress and/or diminished antioxi-
dant capacity are known inducers of HIV replications. An early
study examined the effects of reactive oxygen species (ROS) in
enhancing HIV replication demonstrated the activation of NFkB
under increased oxidative stress (Schreck et al., 1991). The critical
role played by superoxide anions in propagating HIV replication
in human macrophages was later confirmed using a synthetic
peroxynitrite decomposition catalyst, MnTBAP (Aquaro et al.,
2007). Removal of peroxynitrite resulted in significant reduction
in viral replication, in addition to inhibition of lipid peroxidation.
Similar interaction between oxidative stress and HIV replication
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has been observed in clinical samples. For example, compared to
HIV-infected patients, in HIV/HCV co-infected patients, higher
HIV replication was observed in association with diminished
antioxidant capacity to counter the oxidative stress (Shin et al.,
2012). Likewise, daily supplements of vitamins C and E to HIV
patients resulted in reduced levels of markers for oxidative stress
and a trend toward decreased viral load (Allard et al., 1998). Since
cigarette smoke is a well-documented inducer of oxidative stress
(van der Vaart et al., 2004; Aseervatham et al., 2013), compared
to HIV-infected non-smokers, increased HIV replication can be
rationalized in HIV positive smokers.
In addition to examining smoking-induced increased oxida-
tive stress, our previous works have investigated the possible
involvement of CYPs in regulating smoking-mediated enhanced
HIV replication (For review, see Ande et al., 2013). Nicotine-
mediated increased production of ROS was confirmed in both
U937 cells and SVGAastrocytes (Ande et al., 2012; Jin et al., 2012).
In monocytes/macrophages, a major cellular target and reservoir
for HIV (Crowe et al., 2003; Jusino, 2014), we have reported
a significant role of CYP isoform 2A6 in metabolism of major
cigarette constituent, nicotine (Jin et al., 2012). Importantly, in
human monocytic U937 cells, CYP2A6-mediated metabolism of
nicotine and its metabolite was found to be primarily responsible
for generation of procarcinogenic substrates including nicotine
derived nitrosamine ketone (NNK; Jin et al., 2012). Similarly, in
human astrocytes, the cellular target implicated in HIV-induced
neuroAIDS (Eugenin et al., 2011; Henderson et al., 2012), CYP
isoforms 1A1 and 2A6 were found to be significantly upregulated
following treatment with nicotine (Ande et al., 2012). Moreover,
inhibition of the CYP2A6 isoform was associated with significant
attenuation of nicotine metabolism. The influence of cigarette
smoking on CYP induction was further confirmed in a study
wherein significantly increased nicotine metabolism has been
observed in HIV-smokers as compared to HIV-positive non-
smokers (Earla et al., 2014). A recent report by our group con-
firmed enhanced oxidative stress in monocytes, as indicated by
increased DNA damage, from HIV positive smokers compared
to non-smokers (Ande et al., 2015). This increase in oxidative
stress was associated with unchanged levels of major antioxidant
enzymes and enhanced expression of CYPs. Overall, in addition
to increased ROS production, these studies have suggested a
strong interaction between nicotine and CYPs isoforms, which
may contribute toward enhanced HIV replication in HIV positive
smokers.
Polycyclic Aromatic Hydrocarbons and
Cytochrome P450s
In addition to themain psychoactive ingredient nicotine, cigarette
smoke is known to contain hundreds of (PAHs; Snook et al., 1975).
This class of non-polar compounds is known to mediate some
of the toxic effects associated with cigarette smoke. Following
exposure, several enzymes are responsible for the metabolism and
detoxification of PAHs (Shimada, 2006). Importantly, as outlined
in Figure 1, bioactivation of PAH by CYP enzymes, isoform 1,
have been identified critical in rendering toxicity to these com-
pounds (Burczynski et al., 1999). Moreover, cigarette smoke and
FIGURE 1 | Schematic representation of the cytochrome P450
(CYP)-mediated effects of polycyclic aromatic hydrocarbons (PAHs)
on HIV pathogenesis. PAHs are known inducers of CYP1A1/1A2/1B1 and
these CYP enzymes are responsible for metabolism and activation of PAHs.
Activated PAHs and oxidized metabolites mediate increased production of
reactive oxygen species, oxidative stress, and DNA-adduct formation. These
cellular changes, in turn, are known to enhance HIV replication and mediate
carcinogenicity. Increased ROS production, on the other hand, in tumor cells
due to mitochondrial dysfunctioning, for instance, can be rationalized to
facilitate HIV replication. Targeting the overexpressed CYP 1 enzymes,
therefore, serves as a rational clinical approach to impact the incidence of
cancer and viral replication in HIV positive smokers.
PAHs are known to induce expression of CYP1 enzymes via
activation of aryl hydrocarbon receptor (AHR)-regulated path-
way (Nebert et al., 2004), thereby sustaining the PAH-mediated
toxicity. Activation of AHR is followed by nuclear translocation
and complex formation with AHR nuclear translocator (ARNT),
which results in enhanced expression of CYP enzymes, in particu-
lar the isoforms 1A1, 1A2, and 1B1 (Kawajiri and Fujii-Kuriyama,
2007).
Polycyclic aromatic hydrocarbons, in addition to other cigarette
constituents, have been classified as highly carcinogenic com-
pounds, and are delivered through cigarette smoke. For instance,
at least 10 carcinogenic PAHs have been quantified inmainstream
cigarette smoke (Ding et al., 2007). Amongst the various PAHs,
benzo[a]pyrene (BP) has long been known and studied for its car-
cinogenicity (Hecht, 1999). CYP1-mediated oxidation followed by
bioactivation of BP results in formation of benzo(a)pyrene-7,8-
diol-9,10-epoxide, which is responsible for DNA-adduct forma-
tion in lung tissue of smokers, an established risk factor for lung
tumor (Alexandrov et al., 2010). Moreover, induction of CYP1A1
and CYP1B1 enzymes by BP further potentiates the formation of
carcinogenic DNA adducts (Keshava et al., 2005). Importantly,
CYP1A1 genotype was found to predispose smokers to higher
degree of BP-induced DNA adduct formation (Alexandrov et al.,
2002). Several investigations have, in general, found a significant
association between CYP1 polymorphisms and incidence of sev-
eral types of cancers (Bailey et al., 1998; Kiyohara et al., 2002; Thier
et al., 2002; Long et al., 2006; Sergentanis and Economopoulos,
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2010).Moreover, direct and indirect impact of these specific CYP1
polymorphisms upon the incidence of tobacco-mediated carcino-
genicity have been established (Oyama et al., 2006; Choudhury
et al., 2015).
In addition to the well-established AHR driven cellular path-
way for CYP1A1 induction, new evidence has suggested a p53-
dependent induction of CYP1A1 as an alternate mechanism for
BP (Wohak et al., 2014). Interestingly, a previous study has also
reported the cellular interactions between BP and p53 wherein,
treatment with BP was found to increase the mutability of p53
(Hussain et al., 2001). Mutations in this tumor suppressor protein,
p53, is a common feature in many cancers (Vaughan et al., 2014)
and further elucidates BP-induced carcinogenicity. In addition,
PAH-induced production of ROS has also been implicated in gen-
erating p53mutations, which are known to cause cancer (Yu et al.,
2002). Recent studies have also delineated the cellularmechanisms
propagating BP-mediated cell cycle progression and metastasis of
cancer cells (Guo et al., 2015; Wang et al., 2015).
CYP1B1-mediated PAH toxicity has also been reported in sev-
eral studies. In fact, compared to CYP1A1, higher constitutive
expression of CYP1B1 was found in several organs suggesting
a critical role in regulating the intensity of organ-specific PAH-
toxicity (Heidel et al., 1998; Shimada et al., 2003). Expression
of CYP1B1 is known to be induced in lungs of smokers/ex-
smokers compared to non-smokers (Kim et al., 2004; Port et al.,
2004). Interestingly, an inverse relationship between hepatic lev-
els of CYP1A1 and extent of CYP1B1-mediated PAH toxicity
was reported for BP (Galvan et al., 2003). As reviewed by mul-
tiple groups, data from existing studies indicated that genetic
predisposition to 1B1 polymorphisms can enhance PAH toxic-
ity and chances for subsequent carcinogenic events (Roos and
Bolt, 2005; Li et al., 2015). Moreover, overexpression of CYP1B1
has been observed in several types of cancers (McFadyen et al.,
2001; Tokizane et al., 2005; Su et al., 2009). In agreement with
these analyses, in an earlier study, CYP1B1 null mice were
found to attain protection against the carcinogenic effects of
prototypic PAH, 7,12-dimethylbenz[a]anthracene (Heidel et al.,
2000).
In addition to propagating carcinogenicity, CYP-mediated acti-
vation of PAHs has been implicated in atherogenesis, a major
vascular event contributing toward cardiovascular mortality asso-
ciated with cigarette smoking (Ramos and Moorthy, 2005). Fur-
thermore, deleterious effects of PAHs on viral infections has
been highlighted in a study that reported BP-induced enhanced
replication of human papillomavirus (Alam et al., 2008).
PAH and CYP1 Enzymes: Role in HIV
Pathogenesis
While the impact of smoking on HIV pathogenesis and replica-
tion has been investigated (see Smoking and HIV), the relative
contribution of PAHs toward smoking-induced enhanced HIV
replication has not been studied. Importantly, the effects of AHR-
regulated CYP1 enzymes on HIV pathogenesis remains unclear.
However, an earlier work has insinuated a direct interaction
between expression levels of CYP1 enzymes and HIV replication.
For instance, induction of AHR and AHR-regulated CYP1A1
enzymes by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) was
associated with enhanced activity of HIV RNA-dependent DNA
polymerase and increased expression of viral protein in human T-
cells (Tsyrlov and Pokrovsky, 1993). A subsequent study revealed
TCDD-induced activation of HIV-1 gene expression via an oxida-
tive stress-dependent pathway involving CYP1A1 (Yao et al.,
1995).
In addition, recent evidence suggests that predisposition to
specific variants of CYP1A1 polymorphs is associated with sig-
nificant reduction in efficacy of antiretroviral therapy in HIV
positive patients (Feldman et al., 2009). A possible explanation
provided for this observation was the enhanced ability of CYP1A1
to generate DNA adduct forming metabolites that enhance HIV
replication. Moreover, the existing literature provides strong evi-
dence for PAH-mediated enhancedROSproduction and oxidative
stress (Song et al., 2011; Tsuji et al., 2011; Perumal Vijayaraman
et al., 2012), known inducers of viral replication (see Smoking-
mediated Enhanced HIV Replication: Implicated Mechanisms).
Recently, we have observed that CYP1A1 is highly induced in CSC
treated-humanmonocytic cells, a major HIV target and reservoir,
via AHR-mediated pathway (Rao et al., 2015). Overall, the existing
literature warrants detailed studies on investigation of the effects
of cigarette derived PAHs and CYP isoforms induced by cigarette
constituents on HIV replication.
Concluding Remarks
Existing literatures provide ample evidence to support the deteri-
orating effects of cigarette smoking on HIV infection. While the
study of the effects of nicotine has gained preference, the lack of
studies focused on determining the role of PAHs in modulating
HIV replication is concerning. In addition to upregulating other
CYP isoforms, cigarette/tobacco are known to be strong inducers
of CYP 1 enzymes. Importantly, CYP family 1 enzymes play a
critical role in modulating the toxicity associated with PAHs.
Our recent data on CSC-induced enhanced HIV replication in
primarymacrophages (Ande et al., 2015) provides compelling evi-
dence supporting the effects of cigarette constituents in promoting
HIV pathogenesis. We rationalize the enhanced CYP1 expression
followingCSC treatment inHIV-infectedmacrophages (Rao et al.,
2015) to be directly responsible for the observed enhancement in
HIV replication. Based on the existing literature supporting the
deleterious effects of PAHs, current studies have been designed to
study the impact of specific PAHs including BP on HIV replica-
tion.
The CYP family 1 enzymes represent an important junction
for PAH-mediated enhanced risk for cancer and increased HIV
replication (Figure 1). Since there is an association between
long-term HIV infection and increased prevalence of cancer in
these patients (Engels et al., 2006; Yanik et al., 2013), CYP1-
mediated activation of PAHs in smokers can be rationalized to
impact the life expectancy in HIV positive smokers. Alternatively,
a prominent opinion suggests cancer to be a metabolic disease
implicating metabolic dysfunction as the underlying mechanism
(Seyfried and Shelton, 2010). Since metabolic dysfunction is
known to be associatedwith increasedROSproduction and oxida-
tive stress, tumorigenicity can be rationalized to facilitate HIV
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replication. Hence, it is critical to further delineate the underly-
ingmechanisms that govern the smoking/PAH-mediated changes
in HIV replication. Targeting the cellular pathways contributing
to CYP1-mediated responses are expected to provide insights
into molecular mechanisms underlying co-morbidities in HIV-
smokers.
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